31 results about "Thrombotic risk" patented technology

The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and / or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and / or atherosclerosis.

The invention provides a pipe for preparing a stent and a preparation method thereof, a stent and a preparation method thereof. The outer layer of the pipe, the middle layer of the pipe and the inner layer of the pipe are sequentially arranged from outside to inside along the radial direction of the pipe, the outer layer of the pipe and the inner layer of the pipe are both composed of biodegradable polymers, and the middle layer of the pipe is composed of Woven from biodegradable fibers. The stent prepared from the tube of the present invention contains a biodegradable fiber braided structure, which can provide effective radial support force in large-diameter cavities, and the biodegradable fiber braided structure is wrapped in a degradable polymer, which can ensure The stent has good bending deformation properties, which enables the stent to be applied to various blood vessels, and reduces the risk of fatigue fracture caused by the expansion and contraction process of the stent after the stent is implanted in the blood vessel. Compared with the existing biodegradable polymer stent, the stent of the present invention has a thin wall, which facilitates the promotion of endothelialization and reduces the risk of thrombosis caused by stent implantation.

The invention discloses a double-compartment venous port access as well as a using method of venous transfusion and drug storage sustained release thereof. The venous port access comprises an infusioncatheter and a cylindrical access body which is formed by medical silica gel, wherein the access body comprises a cavity; two ends of the access body are of hemispherical structure; the cavity is provided with a diaphragm, so that the cavity is divided into two compartments; the diaphragm is provided with pores by which liquid can permeate; and the infusion catheter is connected to one end of theaccess body and communicates with one of the compartments. The method comprises the following steps: implanting the double-compartment venous port access into a human body; penetrating an intravenousinjection into the compartment which communicates with the infusion catheter and conducting infusion; penetrating a fine-needle syringe into the other compartment of the venous port access to injectan anticoagulant or an antibacterial agent, so that the anticoagulant or the antibacterial agent is slowly released towards tissues around the compartment and / or the venous port access communicating with the infusion catheter via the diaphragm. The double-compartment venous port access is convenient for surgical implantation, and the venous port access is small in surgical incision and convenientfor puncture and infusion operations; and moreover, risks of thrombus and secondary infection can be effectively reduced.

The invention discloses a novel nanofiber vascular stent material with dual-drug loading and step-by-step slow-release functions and a preparation method thereof. The immunoglobulin IgG antibody coupled to the outer layer of the stent material stimulates cells to form epithelial tissue and reduces the formation of thrombus risk; due to the decomposition of polylactic acid in the outer layer of the scaffold, the penicillin loaded by it is slowly released, which inhibits the division and growth of abnormal cells; due to the decomposition of the nitric oxide donor bound to chitosan in the inner layer of the scaffold, the nitric oxide is slowly released freely base, to dilate blood vessels and inhibit tumor growth; the scaffold material has the function of loading penicillin and nitric oxide dual drugs, and releases drugs layer by layer, and is expected to be clinically used as a new type of multifunctional vascular stent implanted in the patient's heart Coronary arteries can achieve many postoperative therapeutic effects such as supporting the lesion blood vessels, reducing the risk of thrombus, inhibiting cytopathy, expanding blood vessels by free radicals, and inhibiting tumor growth.

The invention discloses a medicine for preventing and treating restenosis after coronary artery stent implantation and a preparation method thereof, which comprises the following raw materials in parts by weight: 800-1200 parts of tanshinone, 200-300 parts of hirudin, 20-30 parts of borneol, 6-9 parts of muscone are made into 1000 parts. The invention has the characteristics of good curative effect, no toxic and side effects, can reduce the incidence of restenosis after coronary artery stent implantation, obviously improve the clinical symptoms of patients, reduce the long-term thrombosis risk of patients, and the like, and has remarkable clinical curative effect. It provides a new option for preventing restenosis (ISR) after coronary stent implantation.